Meeting
2024 ASCO Annual Meeting
Conversion surgery for tislelizumab combined chemotherapy for T4a/N3 esophageal squamous cell carcinoma (ESCC): A prospective, single-arm, phase II study.
Authors
Chen Zhang
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Chen Zhang , Xiaobin Shang , Jie Yue , Chuangui Chen , Xiaofeng Duan , Zhao Ma , Zuoyu Chen , Shangren Wang , Gang Zhao , Liang Liu , Weihong Zhang , Runmei Li , Yanjuan Xiong , Fan Yang , Jianyu Xiao , Fuliang Cao , Feng Guo , Dejun Zhou , Xiubao Ren , Hongjing Jiang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer - Local-Regional Disease
Clinical Trial Registration Number
NCT05449483
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 4069)
DOI
10.1200/JCO.2024.42.16_suppl.4069
Abstract #
4069
Poster Bd #
49
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A randomized, placebo-controlled, phase III trial-in-progress to evaluate the efficacy and safety of tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma (ESCC).
First Author: Jian-Ming Xu
Poster
2024 ASCO Annual Meeting
Final analysis of the randomized phase 3 ESCORT-1st trial: Camrelizumab plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma.
First Author: Huiyan Luo
Poster
2023 ASCO Annual Meeting
Efficacy and safety of camrelizumab combined with chemotherapy versus chemotherapy alone as preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma: Preliminary results from a multicenter, prospective, randomized controlled study.
First Author: Renquan Zhang
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Anlotinib combined with paclitaxel and cisplatin as neoadjuvant treatment for esophageal squamous cell carcinoma (ESCC).
First Author: GONGQIAN JIANG